5 news items
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BLRX
17 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
BLRX
4 Mar 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
BLRX
28 Feb 24
in Israel, and with operations in the U.S., the company is driving innovative therapeutics
- Prev
- 1
- Next